Bristol Myers Squibb Invests $2.3B in Houston Biologics Campus

Bristol Myers Squibb Plans New Biologics Manufacturing Campus

Bristol Myers Squibb has announced a major industrial project in Houston, Texas, as part of its effort to expand its pharmaceutical manufacturing operations in the United States. The investment totals about $2.3 billion, while the new facility will be located at Generation Park.

The project is part of the company’s broader commitment to invest $40 billion in the United States over five years, covering research and development, technology, and domestic manufacturing.

A New Campus for Biologics Manufacturing

Bristol Myers Squibb plans to build a manufacturing campus spanning about 600,000 square feet. The company describes the facility as a flexible, multi-modal manufacturing campus designed to support the long-term expansion of its capabilities, scale, and workforce.

The campus is expected to focus on manufacturing small molecules, biologics, and antibody-drug conjugates, areas associated with the development and production of advanced medicines.

Nearly 500 Skilled Jobs in Houston

According to the company’s announcement, the project is expected to create nearly 500 skilled jobs. Other reports have also indicated that about 2,000 additional construction and indirect jobs could be created between 2027 and 2030.

These figures should not be combined into a single job total because the nearly 500 figure refers to skilled jobs at the campus, while the 2,000 figure refers to construction and indirect jobs.

Why Did the Company Choose Houston?

Bristol Myers Squibb said Houston was selected after an extensive competitive evaluation that considered multiple markets across the central and eastern United States.

Reports identified several factors that helped Houston win the project, including its life sciences workforce, available incentives, utilities and transportation infrastructure, and business climate.

Part of a $40 Billion U.S. Investment

The Houston project is part of Bristol Myers Squibb’s broader plan to invest $40 billion in the United States over five years. According to the company’s announcement, the plan includes investment in research and development, technology, and domestic manufacturing.

The expansion is also tied to Bristol Myers Squibb’s focus on strengthening its manufacturing capabilities in the United States and supporting domestic supply chains for advanced medicines.

Construction and Expected Opening Date

According to ABC13 Houston, construction of the facility is expected to begin next year, with the facility scheduled to come online in 2030. These timing details go beyond the information in the company’s announcement, which does not confirm all of these dates in the available company materials. For that reason, the timeline is attributed to the local coverage.

Some reports also contain a discrepancy over the facility’s size. ABC13 reported 60,000 square feet in one reference, while Bristol Myers Squibb’s announcement states that the campus will cover about 600,000 square feet. The 600,000-square-foot figure is the one stated in the company’s official announcement.

Supporting Pharmaceutical Manufacturing in the U.S.

Reports link the project to Bristol Myers Squibb’s broader push to increase investment in manufacturing, research and development, and technology in the United States. The facility is also viewed as part of efforts to strengthen domestic supply chains for advanced medicines.

However, describing the pharmaceutical and healthcare sector as a safe investment haven offering strong returns is not a confirmed fact contained in the core sources about the project. It should therefore be treated as separate investment commentary or analysis rather than a direct claim in the company’s announcement.